Lumenis showcased its new OptiLight technology for the treatment of dry eye disease (DED) to the Australian and New Zealand market at a recent virtual event, sharing insights into its application for clinics and their patients.
“OptiLight is the first and only intense pulsed light (IPL) technology to be FDA-approved for management of dry eye disease due to meibomian gland dysfunction (MGD), the leading cause of dry eye disease,” said Tracey Cannon, Lumenis ANZ marketing director. “OptiLight is a validated and clinically proven patented technology, specifically developed for eyecare practitioners. The simple user interface with preset treatment protocols makes this device very easy to use.”
Dr Jason Holland, lead clinical optometrist at The Eye Health Centre in Queensland, demonstrated the technology at the event, saying OptiLight has become an essential tool in his clinic’s dry eye toolkit. “We deal with dry eye disease every day and have found that to make a meaningful impact on the disease, we need to address the underlying inflammation. Lumenis’ OptiLight technology helps us to address inflammation, as shown in published clinical trials, which improves the signs and symptoms of dry eye disease due to MGD.”
The opportunity is huge, said Cannon. “On average, 30% of patients seeking treatments from an optometrist have symptoms consistent with DED. Keeping these patients in practice and not referring them out gives ECPs the opportunity to retain this returning dry eye revenue as well as gain new patients as they refer friends and family.”
Lumenis also announced that well-known Australian TV journalist Melissa Doyle will be the official OptiLight ambassador in Australia and New Zealand. “As one of Australia’s favourite personalities and a long-term sufferer of eye problems, Melissa was the perfect choice,” Cannon said.
